Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· October 9, 2026
McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?
View original at finance.yahoo.comMcKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified? McKesson Corporation (NYSE:MCK) is expanding its specialty healthcare operations through a $5.8 billion acquisition (including debt) of Option Care Health, Inc…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
McKesson raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00 from $43.80-$44.60.
60% confidencePrecision Medicine Group is expected to strengthen McKesson's oncology and clinical research capabilities, though the financial payoff from its specialty-care portfolio depends on successful integration.
60% confidence
Cité dans ces articles de Via News
- Cancer-drug approvals are stacking up in Q4 2026, but the AI promises and Summit's cash needs are what to check →
- Oncology's Busy Autumn: A Cash-Burning Drugmaker Awaits Its Verdict While AI Promises Faster Medicines →
- Oncology's Next Wave Meets Its Test: Summit's Nov. 14 Ivonescimab Decision, a Record Loss, and AI Claims That Are Still Forecasts →
- Oncology's Three Bets: New Drug Types, AI-Built Medicines and a $5.8 Billion Care Deal, and the Cash Behind One Closely Watched Drug →
